This trial excluded patients with very severe liver disease with prothrombin time (PT) <25%, bilirubin level >10 mg/l or creatinine level >2 mg/dl or with a history of chronic encephalopathy or with HCC and included 75 patients having survived a first SBP episode [3]. Here, F2 is linked to hepatocellular carcinoma.